Previous 10 | Next 10 |
Kamada press release (NASDAQ:KMDA): Q4 GAAP EPS of -$0.11 misses by $0.10. Revenue of $31.47M (-0.1% Y/Y) beats by $9.56M. For further details see: Kamada GAAP EPS of -$0.11 misses by $0.10, revenue of $31.47M beats by $9.56M
REHOVOT, Israel, March 15, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today issued the Letter to Shareholders from Amir London, Chief Executive Officer. ...
Total Revenues for Fiscal Year 2021 were $ 10 3 . 6 Million and Fourth Quarter 202 1 Revenues were $ 31.5 Million . Fiscal Year 2022 Revenues a re Expected to Range Between $125...
Kamada (NASDAQ:KMDA) is scheduled to announce Q4 earnings results on Tuesday, March 15th, before market open. The consensus EPS Estimate is -$0.01 and the consensus Revenue Estimate is $21.91M (-30.4% Y/Y). For further details see: Kamada Q4 2021 Earnings Preview
ANIP, ATNX, BBI, OTCQX:CCHWF, CTRN, DOLE, DTIL, GMDA, KMDA, KNDI, KPLT, NRP, OTCPK:RWEOY, SYRS For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Tuesday's open
REHOVOT, Israel, March 14, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today announced the appointments of two executives to its U.S. leadership team. The Comp...
REHOVOT, Israel, March 02, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will release financial results for the fourth quarter and fiscal year ended December 31, 2021, prior to the open of the U.S. financial...
The FDA has updated the Emergency Use Authorization ("EUA") for the use of convalescent plasma as a COVID-19 treatment for patients with immunosuppressive disease or receiving immunosuppressive treatment. The FDA reiterated that the plasma product used must have high titers of anti-SARS-CoV-2...
Start Time: 08:30 End Time: 08:55 Kamada Ltd. (KMDA) Q3 2021 Earnings Conference Call November 22, 2021, 08:30 AM ET Company Participants Amir London - CEO Chaime Orlev - CFO Bob Yedid - LifeSci Advisors, LLC Conference Call Participants Anthony Petrone - Jefferies Presentation Operator Hello...
Kamada (NASDAQ:KMDA) announced the acquisition of four FDA-approved plasma-derived hyperimmune products from Saol Therapeutics for an upfront payment of $95M. Per the terms, Saol is also entitled to receive up to $50M based on sales milestones during 2022-2034. In addition, Kamada (KMDA)...
News, Short Squeeze, Breakout and More Instantly...
2024-07-17 17:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-17 04:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...